Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates
Company on track for first NDA submission in a gynecologic malignancy in 2026 with a cash balance of $517 million
Source: yahoo.com
Mark Lackner News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mark Lackner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mark Lackner Today - Breaking & Trending Today
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on...
Source: marketscreener.com
Zentalis Pharmaceuticals Shares Hit All-Time Low
By Dean Seal Shares of Zentalis Pharmaceuticals fell to an all-time low after its co-founder said he would step down as chief scientific officer and the...
Source: marketwatch.com
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy... | April 17, 2023
Source: marketscreener.com